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Abstract 
AIM: To evaluate the association between VEGF-634G>C gene polymorphism with premalignant gastric lesions 
as well as the level of VEGF. 
METHODS: This cross-sectional study included patients with H. pylori gastritis at Haji Adam Malik General 
Hospital, Permata Bunda General Hospital, and Universitas Sumatera Utara Hospital, Medan, Indonesia. 
Detection of H. pylori infection was made using positive results of 
14
C-UBT, rapid urease test, and/or 
immunohistochemistry. Gastric premalignant lesion diagnosis was made when one or more of the following were 
present: chronic atrophic gastritis, intestinal metaplasia, or dysplasia. Real-time polymerase chain reaction (RT-
PCR) was used to examine VEGF-634G>C gene polymorphism. Additionally, serum samples of patients with H. 
pylori gastritis were obtained to determine the level of circulating VEGF. Data were analysed using SPSS version 
22.  
RESULTS: A total number of 87 patients with H. pylori gastritis were included in this study. Of all participants, 26 
patients (29.9%) showed gastric premalignancy. There was a significant association between GG+GC genotype 
of VEGF-634G>C and gastric premalignant lesions (P = 0.003; OR (CI 95%) = 6.07 (1.88-41.71)). VEGF-634 
G>C polymorphism also showed an association with VEGF serum levels (P = 0.005). Patients with the GG+GC 
genotype would be at risk of 3.16 times to have high VEGF levels compared to CC genotypes. 
CONCLUSION: VEGF-634G>C polymorphism, in particular, GG+GC genotype was associated with an increased 
risk of gastric premalignant transformation as well as having high VEGF levels in patients with H.pylori gastritis. 
 
 
 
 
 
 
 
 
Introduction 
 
Gastric cancer remains to be the second 
leading cause of all cancer mortality, causing 
approximately 700.000 death worldwide [1]. Gastric 
carcinogenesis is a continuous process commonly 
initiated with atrophic gastritis [2].
 
Chronic atrophic 
gastritis is considered the first step in a sequence of 
mucosal changes in the stomach leading to cancer. 
The current model for stomach carcinogenesis begins 
with gastritis, proceeding to chronic atrophic gastritis, 
then to intestinal metaplasia, dysplasia and, finally, 
carcinoma [3]. Risk factors of gastric cancer are 
Helicobacter pylori (H. pylori) infection, salt intake, 
smoking, alcohol, family history of gastric cancer, and 
presence of premalignant gastric lesions such as 
atrophic gastritis, intestinal metaplasia, and dysplasia. 
Gastric premalignant lesions are well-known risk 
factors for the development of gastric cancer [4] [5] [6] 
[7] [8] [9] [10] [11] [12]. 
H. pylori infection has been well studied as 
the main aetiology of chronic gastritis. Subsequently, 
atrophic gastritis, intestinal metaplasia, dysplasia, and 
gastric cancer may follow. Not all patients with H. 
pylori infection would develop such progression. One 
other factor that may contribute to the malignant 
progression is genetic [13].
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Previous evidence suggests the Vascular 
Endothelial Growth Factor (VEGF) may play a role in 
gastric carcinogenesis, as VEGF promotes 
angiogenesis that is required for tumour survival and 
metastasis [14].
 
Patients with premalignant lesions 
such as atrophic gastritis, intestinal metaplasia, and 
dysplasia also show overexpression of VEGF that 
may contribute in the early step of carcinogenesis 
[15]. 
 The VEGF gene, located at 6p21.3 
chromosome, composed of 8 exons separated by 7 
introns, is a very polymorphic gene (about 140 
variants) [16] [17].
 
Previous studies show VEGF-
634G>C polymorphism to be associated with an 
increased risk of gastric cancer as well as elevated 
VEGF levels. This polymorphism is influenced by 
ethnicity to previous studies showed different results 
[18] [19] [20] [21].
 
There were no similar studies in 
Southeast Asia after searching on PubMed. To the 
authors' knowledge, no published studies evaluating 
the association between VEGF-634G>C 
polymorphism with gastric premalignant lesions and 
serum VEGF levels in H. pylori gastritis patients are 
available. This study was conducted to determine the 
association between VEGF-634G>C polymorphism 
with premalignant gastric lesions and serum level of 
VEGF in H. pylori gastritis patients.
 
 
 
Methods 
 
Patients Selection  
This study was a cross-sectional study on 87 
consecutive H. pylori gastritis patients that were 
admitted to the Endoscopy Unit at Haji Adam Malik 
General Hospital, Permata Bunda General Hospital, 
and Universitas Sumatera Utara Hospital, Medan, 
Indonesia between October and December 2017. 
Inclusion criteria include gastritis patients diagnosed 
based on histopathological examination, at least 18 
years old, and willing to take part in the study. 
Patients with one of the following criteria were 
excluded: a history of H. pylori eradication treatment 
in the last 6 months or currently on antibiotics therapy 
commonly used in H. pylori eradication; history of 
proton pump inhibitor, H2 receptor antagonist use 
within the past 1 month; patients with systemic 
disease, malignancy or currently pregnant. This study 
was approved by the Institutional Review Board of 
Universitas Sumatera Utara. 
Endoscopy was conducted to evaluate gastric 
mucosae such as the presence of oedema, erythema 
(spotted, patchy, linear), exudate, bleeding, erosion; 
as well as to take a tissue sample for the rapid urease 
test, immunohistochemistry test for H. pylori and 
histopathology. Tissue biopsy was performed within 
the greater and lesser curvature of the distal antrum, 
the lesser curvature at incisura angular, the anterior 
and posterior wall of the proximal corpus. An 
additional biopsy was also done in suspicious regions 
that were not included in the areas mentioned 
previously. 
 
Diagnosis of Gastric Premalignant Lesion  
Microscopic evaluation was done to diagnose 
premalignant gastric lesions such as chronic atrophic 
gastritis, intestinal metaplasia, and dysplasia. The 
presence of one or more findings is positive for a 
premalignant gastric lesion. Histopathologic 
examination was done by two pathologists blindly at 
Universitas Sumatera Utara Medan. If there were 
differences in the results of the examination of both 
experts, then a third pathologist was required to 
perform the histopathological examination. 
 
Helicobacter pylori detection  
The diagnosis of H. pylori infection was made 
using positive results of 
14
C-UBT, rapid urease test, 
and/ or immunohistochemistry. Before the 
14
C-UBT 
examination, the subjects fasted for at least 6 h, 
usually overnight. Patients swallowed 37 kBq (1 μCi) 
of encapsulated 
14 
C urea/citric acid composition in 25 
ml water. Breath samples of patients were collected 
into Heliprobe Breath Cards (Noster system) 10 min 
after administration of 
14
C urea. Patients exhaled into 
the breath card until its colour indicator changed from 
orange to yellow. The breath samples were measured 
using the Heliprobe analyser (Noster system), and the 
activity was counted for 250 s. Results were 
expressed as counts per minute (cpm) and counts < 
25 cpm were defined as Heliprobe 0 = not infected, 
counts between 25 cpm and 50 cpm as Heliprobe 1 = 
equivocal and counts > 50 cpm as Heliprobe 2 = 
infected [22]. 
The rapid urease test (Pronto Dry®, France) 
was also used to establish the diagnosis of H. pylori 
infection. The positive result is indicated by the colour 
changing of the indicator from amber to pink-red at 
room temperature within 24 hours. The yellow 
indicator colour is considered to be negative [23]. 
Immunohistochemical (IHC) staining for 
evaluation of H. pylori status carried-out with the 
procedure as follows [24]. Tissue sections were 
deparaffinized, rehydrated, and pretreated with 
Proteinase K for 8 min and incubated with ChemMate 
peroxidase blocking solution at room temperature for 
10 min. The slides were subsequently incubated with 
the polyclonal rabbit anti- H. pylori primary antibody 
(B0471: Dako Corporation, Glostrup, Denmark) with a 
dilution of 1:50 was conducted at room temperature 
for 1 hour. After samples had been washed 3 times 
with phosphate-buffered saline, the Dako EnVision 
Dual Link System–HRP (K4065: Dako Corporation) 
was applied for 30 minutes. Finally, sections were 
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incubated in diaminobenzidine for 10 minutes, 
followed by hematoxylin counterstaining and 
mounting. H. pylori-infected gastric mucosa from 
chronic gastritis patients served as positive controls. 
Negative controls were obtained by replacing the 
primary antibody with phosphate-buffered saline. H. 
pylori infection in the tissue sections was confirmed 
when short, curved or spiral bacilli resting on the 
epithelial surface, in the mucus layer, or deep in the 
gastric pits could be observed by light microscopy. 
 
Serum Levels of VEGF  
Venous blood samples were drawn into 
serum separator tubes and allowed to clot for 30-45 
minutes at room temperature, before being 
centrifuged for 15 minutes at approximately 1,000 g. 
Serum was immediately stored frozen in aliquots at -
20
o
C until assay for VEGF was performed. Circulating 
VEGF levels were examined in serum using the 
Quantikine Human VEGF-ELISA (Quantikine, R&D 
Systems, Inc., Minneapolis).  
 
VEGF-634 G>C Polymorphism 
  Genomic DNA was extracted and purified 
from peripheral blood using the High Pure PCR 
Template Preparation Kit (Roche Applied Science) 
and stored until processed for genotyping. Analysis of 
the VEGF SNP -634G>C was performed using real-
time polymerase chain reaction (RT-PCR). The PCR 
primers used for the –634G>C polymorphisms were 
5’-CGACGGCTTGGGGAGATTGC-3’ (forward) and 
5'-GGGCGGTGTCTGTCTGTCTG-3’ (reverse). The 
PCR cycle conditions consisted of an initial 
denaturation step at 94°C for 5 min, followed by 35 
cycles of 30 s at 94°C, 30 s at 62°C, 30 s at 72°C and 
a final elongation at 72°C for 10 min. 
 
Statistical Methods  
Data analysis was performed through 
univariate and bivariate (Chi-Square test) analyses 
using SPSS 22nd version (SPSS Inc., Chicago). A 
value of P < 0.05 with a 95% confidence interval was 
considered statistically significant.  
 
 
 
Results 
 
Baseline and clinical characteristics of 
subjects 
A total number of 87 H. pylori gastritis patients 
were included in this study. The diagnosis of H. pylori 
infection was made using positive results of 
14
C-UBT, 
rapid urease test, and/ or IHC. Figure 1 shows H. 
pylori in the gaster tissues by IHC.  
 
Figure 1: H. pylori in the gaster tissues by immunohistochemistry 
(IHC) 
 
Patients’ characteristics show a majority of 
males (63.2%) with a mean age of 50.8 years, with 
mostly Batak ethnicity (52.9%). There were 46 
patients (52.9%) having VEGF-634G>C polymorphism 
GC genotype, followed by 24 patients (27.6%) GG 
genotype and 17 patients (19.5%) CC genotype. The 
median value of VEGF levels was 441.7 pg/mL with a 
minimum level of 80.7 pg/mL and a maximum level of 
2185.2 pg/mL. We grouped VEGF levels into 2 
categories based on the median value, > 442 and 
<442. As many as 48.3% of patients had VEGF >442 
pg/mL, 51.7% of patients had VEGF <442 pg/mL. 
There were 26 patients (29.9%) with premalignant 
gastric lesions (Table 1). 
 
Table 1: Baseline and clinical characteristics of subjects 
Characteristics n (%) 
Gender  
   Male 55 (63.2%) 
   Female 32 (36.8%) 
Age, mean + SD (years) 
   >51 years 
   <51 years 
50.8 + 12.2 
58 (66.7%) 
29 (33.3%) 
Ethnicity  
   Batak 46 (52.9%) 
   Javanese 20 (23%) 
   Aceh 
   Malay 
12 (13.8%) 
9 (10.3%) 
Education 
   Elementary school 
   Middle school 
   High school 
   University 
 
7 (8%) 
12 (13.8%) 
57 (65.5%) 
11 (12.6%) 
BMI, mean + SD (kg/m
2
) 
   Overweight 
   Not overweight 
Gastric Premalignant Lesion 
   Yes 
   No 
VEGF-634 G>C polymorphism 
   GG genotype 
   GC genotype 
   CC genotype 
VEGF level, median (min-max) (pg/ml) 
   High (> 442) 
   Low (< 442) 
22.2 + 3.8 
39 (44.8%) 
48 (55.2%) 
 
26 (29.9%) 
61 (70.1%) 
 
24 (27.6%) 
46 (52.9%) 
17 (19.5%) 
441.7 (80.7 – 2185.2) 
42 (48.3%) 
45 (51.7%) 
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Association between patient’s 
characteristics and VEGF levels with 
premalignant gastric lesions  
There was a significant association between 
age and gastric premalignant lesions (P = 0.020), 
patients > 51 years were at risk of 2.75 times to get 
premalignant gastric lesions compared to age < 51 
years. There was a significant association between 
ethnic group and gastric premalignant lesions (P = 
0.016), where the Batak ethnic group had a 2.97 times 
risk of having premalignant gastric lesions compared 
to non-Bataks. There was a significant association 
between VEGF levels and premalignant gastric 
lesions (P <0.001), where patients with high VEGF 
levels had a 12.86 times risk of having gastric 
premalignant lesions compared to patients with low 
VEGF levels. There were no associations between 
gender, education, and overweight with premalignant 
gastric lesions (P > 0.05) (Table 2). 
Table 2: Association between patients’ characteristic and 
VEGF level with premalignant gastric lesions 
Variables 
Gastric premalignant lesions Total 
p OR (95% CI) 
Present Absent 
Gender     
0.237 
 
0.68 (0.36-1.28)    Male 14 (25.5%) 41 (74.5%) 55 (100%) 
   Female 12 (37.5%) 20 (62.5%) 32 (100%) 
Age     
0.020* 
 
2.75 (1.05-7.24)    >51 years 22 (37.9%) 36 (62.1%) 58 (100%) 
   <51 years 4 (13.8%) 25 (86.2%) 29 (100%) 
Education 
   Low level 
   High level 
 
7 (36.8%) 
19 (27.9%) 
 
12 (63.2%) 
49 (72.1%) 
 
19 (100%) 
68 (100%) 
 
0.454 
 
1.32 (0.65-2.66) 
Ethnic group 
   Batak 
   Non-Batak 
 
20 (43.5%) 
6 (14.6%) 
 
26 (56.5%) 
35 (85.4%) 
 
46 (100%) 
41 (100%) 
 
0.016* 
 
2.97 (1.32-6.67) 
Overweight     
0.436 
 
0.77 (0.4-1.5)    Present 10 (2.6%) 29 (74.4%) 39 (100%) 
   Absent 16 (33.3%) 32 (66.7%) 48 (100%) 
VEGF level     
<0.001* 
 
12.86 (3.24-51.1)    High 24 (57.1%) 18 (42.9%) 42 (100%) 
   Low 2 (4.4%) 43 (95.6%) 45 (100%) 
*P < 0.05; Low level of education : elementary school + middle school; High level of 
education: high school + university. 
 
 
Association between VEGF-634G>C 
polymorphism and premalignant gastric 
lesions  
There was a significant association between 
VEGF-634G>C polymorphism and premalignant 
gastric lesions. GG genotype increased the risk of 
7.08 times for premalignant gastric lesions compared 
to CC genotype (P = 0.014). GC genotype increased 
the risk of 5.54 times for premalignant gastric lesions 
compared to CC genotype (P = 0.048). GG + GC 
genotype was 6.07 times more likely to have 
premalignant gastric lesions than patients with CC 
genotypes (P = 0.003). Patients with the G allele were 
at risk of 1.75 times for premalignant gastric lesions 
compared to C allele (p = 0.022) (Table 3). 
 
Table 3: Association between VEGF-634G>C polymorphism 
and premalignant gastric lesions 
VEGF-634G>C 
Polymorphism 
Gastric premalignant lesion Total 
p OR (95% CI) 
Present Absent 
GG 
GC 
CC 
10 (41.7%) 
15 (32.6%) 
1 (5.9%) 
14 (58.3%) 
31 (67.4%) 
16 (94.1%) 
24 (100%) 
46 (100%) 
17 (100%) 
0.014* 
0.048* 
7.08 (1.2-50.26) 
5.54 (1.79-38.82) 
1 (ref.) 
GG+GC 
CC 
25 (35.7%) 
1 (5.9%) 
45 (64.3%) 
16 (94.1%) 
70 (100%) 
17 (100%) 
0.003* 6.07 (1.88-41.71) 
1 (ref.) 
Allele G 
Allele C 
35 (37.2%) 
17 (21.3%) 
59 (62.8%) 
63 (78.8%) 
94 (100%) 
80 (100%) 
0.022* 1.75 (1.07 – 2.88) 
1 (ref.) 
*P <0.05. 
 
Association between VEGF-634G>C 
polymorphism and serum VEGF levels 
Further analysis was done to evaluate the 
association between VEGF-634G>C polymorphism 
and serum levels of VEGF. GG genotype increased 
the risk of 3.54 times to have high VEGF levels 
compared to CC genotype (P = 0.004). GC genotype 
increased the risk of 2.96 times to have high VEGF 
levels compared to CC genotype (P = 0.014). GG + 
GC genotype was 3.16 times more likely to have high 
VEGF levels than patients with CC genotypes (P = 
0.005). Patients with G allele were at risk 1.53 times 
to have high VEGF levels compared to C allele (P = 
0.009) (Table 4).  
Table 4: Association between VEGF -634 G>C polymorphism 
and the level of serum VEGF 
VEGF-634G>C 
Polymorphism 
VEGF Level Total 
P OR (95% CI) 
High Low 
GG 
GC 
CC 
15 (62.5%) 
24 (52.2%) 
3 (17.6%) 
9 (37.5%) 
22 (47.8%) 
14 (82.4%) 
24 (100%) 
46 (100%) 
17 (100%) 
0.004* 
0.014* 
3.54 (1.21-10.35) 
2.96 (1.02-8.56) 
1 (ref.) 
GG+GC 
CC 
39 (55.7%) 
3 (17.6%) 
31 (44.3%) 
14 (82.4%) 
70 (100%) 
17 (100%) 
0.005* 3.16 (1.11-9) 
1 (ref.) 
Allele G 
Allele C 
54 (57.4%) 
30 (37.5%) 
40 (42.6%) 
50 (62.5%) 
94 (100%) 
80 (100%) 
0.009* 1.53 (1.1 – 2.13) 
1 (ref.) 
*P < 0.05. 
 
 
Discussion 
 
H. pylori is a type 1 carcinogen according to 
the International Agency for Research on Cancer 
(IARC). It promotes malignant changes through 
triggering an inflammatory cascade, including 
neutrophil and monocyte recruitment and upregulation 
of proinflammatory cytokines destroying the gastric 
mucosa. Epidemiological studies have shown an 
association between chronic inflammation and 
malignant transformation. H. pylori may also play a 
role in angiogenesis, essential for malignant cells 
survival. Among angiogenic factors, VEGF is known to 
be the most potent stimulus for neoangiogenesis [3].
 
This VEGF has a mitogenic effect on endothelial cells, 
promotes tumour cell growth, stimulates cell 
migration, and metastasis from the primary site [25].
 
The previous meta-analysis by Chen et al. 
reported higher VEGF expression in Asian patients 
with gastric cancer compared to controls (OR= 
112.41, 95% CI= 64.12 – 197.06). High expression of 
VEGF also showed poor 5-year survival rates (RR= 
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2.45, P = 0.000), indicating its potential use as a 
marker for gastric cancer prognosis [26]. In gastric 
adenocarcinoma, a higher level of VEGF was also 
observed along with the increased density of 
intratumour small vessels. Moreover, higher 
expression of VEGF was also seen in gastric 
premalignant lesions such as chronic atrophic 
gastritis, intestinal metaplasia, and gastric dysplasia; 
as well as gastric carcinoma [15] [27] [28].
 
Raica et al 
also reported there was an association between 
increased levels of VEGF expression with gastric 
carcinogenesis [28].
  
These results are consistent with 
this study, that there was a significant association 
between high VEGF levels and premalignant gastric 
lesions (P <0.001).
 
Several SNP on the VEGF gene is thought to 
affect its expression. Certain allele variation may lead 
to overexpression of the transcription factor that will 
bind to the promoter site, which serves as the initial 
RNA polymerase binding site that will initiate 
transcription [29].
 
A previous study by Oh et al. 
evaluated 190 gastric cancer patients in Korea 
reported that the GG genotype of VEGF-634G>C 
polymorphism was associated with higher VEGF 
serum levels as well as poor outcome in patients with 
advanced stage [21].
 
Similar with that study, this 
present study also found a significant association 
between VEGF-634G>C polymorphism and 
premalignant gastric lesions, in particular, those with 
the GG+GC genotype had an increased risk of 3.16 
fold to have high VEGF levels compared to those with 
the CC genotype.   
A gene polymorphism was not only related to 
an increase or decrease in serum levels, but also with 
susceptibility to certain diseases [16] [30].
 
A study in 
Texas by Guan et al. included 171 gastric cancer 
patients (vs 353 controls) found that  VEGF-
634CG+CC showed an increased risk of gastric 
cancer compared to -634GG genotype [18]. Patients 
with VEGF heterozygous -634GC showed a poorer 1-
year survival compared to patients with VEGF-634GG 
genotype [31].
 
Similar findings were reported by 
Tzanakis et al. (2006) in Greece that evaluated 100 
gastric cancer patients. Tzanakis et al. found the 
VEGF-634CC genotype was associated with 
increased risk of gastric cancer and lower survival 
rates [19]. Meanwhile, a study by Chae et al. (2006) in 
Korea on 413 gastric cancer patients and 413 
subjects as controls showed that VEGF-634CC was 
significantly associated with a lower risk of gastric 
cancer. VEGF-634 C allele was associated with a 
significant reduction in gastric cancer susceptibility 
(OR 0.686; 95% CI 0.564-0.834) [20]. Another study 
in Oman by Al-Moundhri (2009) found a significant 
association between VEGF-634 CC genotype with 
poor tumour differentiation and lymph nodes 
metastasis [32]. There were still limited studies that 
evaluate the relationship of VEGF polymorphism with 
premalignant gastric lesions. Tahara et al. reported 
that 1612G>A polymorphism of the VEGF gene was 
associated with premalignant gastric lesions in older 
individuals. The 1612 GA genotype showed a 
significantly higher incidence of intestinal metaplasia 
in H. pylori-positive individuals whose age was more 
than 65 years old [13]. This current study showed that 
VEGF-634G>C polymorphism was associated with 
premalignant gastric lesions, where -634GG+GC 
genotype increased the risk of 6.07 times for 
premalignant gastric lesions, presumably due to 
elevated serum VEGF levels in those genotypes.  
These study indicated that older age was 
associated with an increased risk of premalignant 
gastric lesions. Previous studies reported a similar 
result [33] [34]. Benberin et al. showed the prevalence 
of premalignant gastric lesions increased with age. 
This condition was rarely seen in individuals under the 
age of 40 years [35]. The majority ethnic group in this 
study were Bataks (52,9%) because Bataks inhabit 
most of the North Sumatera region. There was a 
significant association between ethnicity and 
premalignant gastric lesions. Batak ethnic group 
increased the risk of 2.97 times for premalignant 
gastric lesions (P = 0.016). Further study is required to 
evaluate the high prevalence of premalignant gastric 
lesions in Bataks. Bataks have a habit of consuming 
alcohol both in a traditional ceremony and daily life 
[36].
 
Background of genetic factors, nutritional factors 
or lifestyle, immune responses to H. pylori infection 
may be considered. Ethnic differences may influence 
the risk of premalignant gastric lesions, which may be 
due to genetic variation [37].  
In conclusion, the polymorphism of VEGF-634 
G>C, in particular, GG+GC genotype, was associated 
with an increased risk of premalignant gastric lesions 
and high serum levels of VEGF in patients with H. 
pylori gastritis in Medan, Indonesia. There was a 
significant association between age, ethnic, and 
VEGF levels with premalignant gastric lesions. 
 
 
Acknowledgements 
 
We would like to express our gratitude to 
Lidya Imelda Laksmi who has conducted the 
histopathological analysis in this study, as well as to 
Khairani, Sulasmi, Tiolan, Tiambun who have assisted 
the endoscopy procedure in all patients. 
 
 
References 
 
1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 
2002. CA Cancer J Clin. 2005;55(2): 74-108. 
https://doi.org/10.3322/canjclin.55.2.74 PMid:15761078  
2. Yanaoka K, Oka M, Mukoubayashi C, Yoshimura N, Enomoto S, 
 
Basic Science 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
6                                                                                                                                                                                                    https://www.id-press.eu/mjms/index 
 
Iguchi M, et al. Cancer high-risk subjects identified by serum 
pepsinogen tests: outcomes after 10-year follow-up in 
asymptomatic middle-aged males. Cancer Epidemiol Biomarkers 
Prev. 2008; 17(4):838–45. https://doi.org/10.1158/1055-9965.EPI-
07-2762 PMid:18398025  
3. Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, 
Nakamura H, et al. Progression of chronic atrophic gastritis 
associated with Helicobacter pylori infection increases risk of 
gastric cancer. Int J Cancer. 2004; 109(1):138-43. 
https://doi.org/10.1002/ijc.11680 PMid:14735480  
 
4. Park YH, Kim N. Review of atrophic gastritis and intestinal 
metaplasia as a premalignant lesion of gastric cancer. J Cancer 
Prev. 2015; 20(1):25-40. 
https://doi.org/10.15430/JCP.2015.20.1.25 PMid:25853101 
PMCid:PMC4384712 
 
5. Zullo A, Hassan C, Romiti A, Giusto M, Guerriero C, Lorenzetti 
R, et al. Follow-up intestinal metaplasia in the stomach: when, how, 
and why. World J Gastrointest Oncol. 2012; 4(3):30-6. 
https://doi.org/10.4251/wjgo.v4.i3.30 PMid:22468181 
PMCid:PMC3312926 
 
6. Lage J, Uedo N, Dinis-Ribeiro M, Yao K. Surveillance of patients 
with gastric precancerous conditions. Best Pract Res Clin 
Gastroenterol. 2016; 30(6):913-22. 
https://doi.org/10.1016/j.bpg.2016.09.004 PMid:27938786  
 
7. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J 
Gastroenterol. 2006; 12:354-62. 
https://doi.org/10.3748/wjg.v12.i3.354 PMCid:PMC4066052 
 
8. Song H, Ekheden IG, Zheng Z, Ericsson J, Nyren O, Ye W. 
Incidence of gastric cancer among patients with gastric 
precancerous lesions: observational cohort study in a low risk 
Western population. BMJ. 2015; 351:1-7. 
https://doi.org/10.1136/bmj.h3867 
 
9. Almouradi T, Hiatt T, Attar B. Gastric intestinal metaplasia in an 
underserved population in the USA: prevalence, epidemiologic, 
and clinical features. Gastroenterol Res Pract. 2013; 2013:856256. 
https://doi.org/10.1155/2013/856256 PMid:24235966 
PMCid:PMC3819766 
 
10. Zhang XY, Zhang PY, Aboul-Soud MAM. From inflammation to 
gastric cancer: role of Helicobacter pylori. Oncol Lett. 2017; 13(2): 
543-8. https://doi.org/10.3892/ol.2016.5506 PMid:28356927 
PMCid:PMC5351277 
 
11. Yeh LY, Raj M, Hassan S, Aziz SA, Othman NH, Mutum SS, et 
al. Chronic atrophic antral gastritis and risk of metaplasia and 
dysplasia in an area with low prevalence of Helicobacter pylori. 
Indian J Gastroenterol. 2009; 28(2):49-52. 
https://doi.org/10.1007/s12664-009-0017-0 PMid:19696988  
 
12. de Vries AC, van Grieken NC, Looman CW, Casparie MK, 
Vries E, Meijer GA, et al. Gastric cancer risk in patients with 
premalignant gastric lesions: A Nationwide Cohort Study in the 
Netherlands. Gastroenterology. 2008; 134(4):945-52. 
https://doi.org/10.1053/j.gastro.2008.01.071 PMid:18395075  
 
13. Tahara T, Arisawa T, Shibata T, Nakamura M, Yamashita H, 
Yoshioka D, et al. Effect of polymorphisms in the 3'-untranslated 
region (3'-UTR) of VEGF gene on gastric premalignant condition. 
Anticancer Res. 2009; 29(2):458-90. 
 
14. Chekhonin VP, Shein SA, Korchagina AA, Gurina OI. VEGF in 
tumor progression and targeted therapy. Curr Cancer Drug 
Targets. 2013; 13(4): 423-43. 
https://doi.org/10.2174/15680096113139990074 PMid:23167597  
 
15. Feng CW, Wang LD, Jiao LH, Liu B, Zheng S, Xie XJ. 
Expression of p53, inducible nitric oxide synthase and vascular 
endothelial growth factor in gastric precancerous and cancerous 
lesions: correlation with clinical features. BMC Cancer. 2002; 2:8. 
https://doi.org/10.1186/1471-2407-2-8 PMid:11978184 
PMCid:PMC113262 
 
16. Eng L, Liu G. VEGF pathway polymorphisms as prognostic and 
pharmacogenetics factors in cancer: a 2013 update. 
Pharmacogenomics. 2013; 14(13):1659-67. 
https://doi.org/10.2217/pgs.13.165 PMid:24088136  
 
17. Eng L, Azad AK, Habbous S, Pang V, Xu W, Maitland-van der 
Zee AH, et al. Vascular endothelial growth factor pathway 
polymorphisms as prognostic and pharmacogenetic factors in 
cancer: a systematic review and meta-analysis. Clin Cancer Res. 
2012; 18(17):4526–37. https://doi.org/10.1158/1078-0432.CCR-12-
1315 PMid:22733538  
 
18. Guan X, Zhao H, Niu J, Tang D, Ajani JA, Wei Q. The VEGF -
634G>C promoter polymorphism is associated with risk of gastric 
cancer. BMC Gastroenterol. 2009; 9:77. 
https://doi.org/10.1186/1471-230X-9-77 PMid:19835575 
PMCid:PMC2771032 
 
19. Tzanakis N, Gazouli M, Rallis G, Giannopulous G, 
Papaconstantinou I, Theodoropoulos G, et al. Vascular endothelial 
growth factor polymorphisms in gastric cancer development, 
prognosis, and survival. J Surg Oncol. 2006; 94(7):624-30. 
https://doi.org/10.1002/jso.20619 PMid:17111394  
 
20. Chae YS, Kim JG, Sohn SK. Investigation of vascular 
endothelial growth factor gene polymorphisms and its association 
with clinicopathologic characteristics in gastric cancer. Oncology. 
2006; 71:266-72. https://doi.org/10.1159/000106788 
PMid:17671399  
 
21. Oh SY, Kwon HC, Kim SH, Lee S, Lee JH, Hwang JA, et al. 
The relationship of Vascular endothelial growth factor gene 
polymorphisms and clinical outcome in advanced gastric cancer 
patients treated with FOLFOX: VEGF polymorphism in gastric 
cancer. BMC Cancer. 2013; 13:43. https://doi.org/10.1186/1471-
2407-13-43 PMid:23374220 PMCid:PMC3573956 
 
22. Mansour-Ghanaei F, Sanaei O, Joukar F. Clinical Validation of 
an Office-Based 14C-UBT (Heliprobe) for H. pylori Diagnosis in 
Iranian Dyspeptic Patients. Gastroenterol Res Pract. 2011; 
2011:930941. https://doi.org/10.1155/2011/930941 PMid:21760778 
PMCid:PMC3132501 
 
23. Rojborwonwitaya J, Vijitjunykul N. Comparison of the accuracy 
of two commercial rapid urase tests, CLOtest®, and Pronto Dry®, 
in detecting Helicobacter pylori Infection. Thai J Gastroenterol. 
2005; 6(2):55-60. 
 
24. Wang F, Sun GP, Zou YF, Zhong F, Ma T, Li XQ, et al. 
Helicobacter pylori infection predicts favorable outcome in patients 
with gastric cancer. Curr Oncol. 2013; 20(5):e388-95. 
https://doi.org/10.3747/co.20.1417 PMid:24155636 
PMCid:PMC3805408 
 
25. Tarnawski AS, Chai J, Jones MK. Esophageal and 
gastrointestinal microcirculation: essential for mucosal protection, a 
target for injury, and a critical component of injury and ulcer 
healing. In: Ishii H, Suematsu M, Tanishita K (eds). Organ 
microcirculation: a gateway to diagnostic and therapeutic 
intervention. Tokyo: Springer, 2005:49-61. 
https://doi.org/10.1007/4-431-27174-0_7 
 
26. Chen J, Li T, Wu Y, He L, Zhang L, Shi T, et al. Prognostic 
significance of vascular endothelial growth factor expression in 
gastric carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 
2011; 137(12):1799–812. https://doi.org/10.1007/s00432-011-
1057-2 PMid:21918901  
 
27. Tuccillo C, Cuorno A, Rocco A, Martinelli E, Staibano S, 
Mascolo M, et al. Vascular endothelial growth factor and neo-
angiogenesis in H. pylori gastritis in humans. J Pathol. 2005; 
207(3):277–84. https://doi.org/10.1002/path.1844 PMid:16184519  
 
28. Raica M, Mogoant˘a L, Cimpean AM, Alexa A, Ioanovici S, 
M˘arg˘aritescu C. Immunohistochemical expression of vascular 
endothelial growth factor (VEGF) in intestinal type gastric 
carcinoma. Rom J Morphol Embryol. 2008; 49(1):37-42. 
PMid:18273500  
 
29. Corvalan AH, Carrasco G, Saavedra K. The genetic and 
epigenetic bases of gastritis. In Mozsik G (ed). Current Topics in 
Gastritis. London: In Tech, 2012:79-95. 
 
30. Sripichai O, Fucharoen S. Genetic polymorphisms, and 
implication for human diseases. J Med Assoc Thai. 2007; 
90(2):394-8. PMid:17375650  
 
31. Guan X, Zhao H, Niu J, Tan D, Ajani JA, Wei Q. 
Polymorphisms of TGFβ1 and VEGF genes and survival of patients  
 Siregar et al. VEGF-634G>C Gene Polymorphism, Gastric Premalignant Lesions and Serum VEGF Levels 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci.                                                                                                                                                                                                         7 
 
with gastric cancer. J Exp Clin Cancer Res. 2009; 28(1):94. 
https://doi.org/10.1186/1756-9966-28-94 PMid:19566948 
PMCid:PMC2717936 
32. Al-Moundhri MS, Al-Nabhani M, Burney IA, Al-Farsi A, Al-
Bahrani B. Gastric cancer risk predisposition and prognostic 
significance of vascular endothelial growth factor (VEGF) gene 
polymorphisms – a case-control study in an Omani population. Mol 
Carcinog. 2009; 48(12):1170-6. https://doi.org/10.1002/mc.20572 
PMid:19676106  
 
33. Kim N, Park YS, Cho SI, Lee HS, Choe G, Kim IW, et al. 
Prevalence and risk factors of atrophic gastritis and intestinal 
metaplasia in a Korean population without significant gastro-
duodenal disease. Helicobacter. 2008;13:245–55. 
https://doi.org/10.1111/j.1523-5378.2008.00604.x PMid:18665932  
 
34. den Hoed CM, van Eijck BC, Capelle LG, van Dekken H, 
Biermann K, Siersema PD, et al. The prevalence of premalignant 
gastric lesions in asymptomatic patients: predicting the future 
incidence of gastric cancer. Eur J Cancer. 2011; 47:1211-8. 
https://doi.org/10.1016/j.ejca.2010.12.012 PMid:21239166  
 
35. Benberin V, Bektayeva R, Karabayeva R, Lebedev A, 
Akemeyeva K, Paloheimo L, et al. Prevalence of H. pylori Infection 
and Atrophic Gastritis Among Symptomatic and Dyspeptic Adults in 
Kazakhstan. A Hospital based Screening Study Using a Panel of 
Serum Biomarkers. Anticancer Res. 2013; 33:4595-6. 
PMid:24123036  
 
36. Gaol NL, Husin. Dilema pemberantasan minuman keras 
terhadap pelestarian budaya masyarakat Batak Toba (studi kasus 
di Desa Ria-Ria Kecamatan Pollung Kabupaten Humbang 
Hasundutan). Citizenship. 2013; 1:101-21. 
 
37. Maran S, Lee YY, Xu S, Rajab N, Hasan N, Aziz SH, et al. 
Gastric precancerous lesions are associated with gene variants in 
Helicobacter pylori-susceptible ethnic Malays. World J 
Gastroenterol. 2013; 19:3615-22. 
https://doi.org/10.3748/wjg.v19.i23.3615 PMid:23801863 
PMCid:PMC3691040 
 
  
